A Phase 2 interventional study of Auranofin and Placebo in Amoebic Dysentery and Giardiasis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 2 sites in Bangladesh. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase IIa, randomized, placebo-controlled, single-blinded superiority treatment study in males and non-pregnant females, 18 to 65 years of age who are in good health. This study is designed to compare placebo to once daily doses of 6mg auranofin for adults with amebiasis or giardiasis. A sample size of 68 subjects enrolled with amebiasis (34 per arm) and 68 with giardiasis (34 per arm); Power based on 60 subjects with amebiasis and 60 with giardiasis completing the study.Eligible subjects will be randomly assigned to a treatment group with auranofin (6 mg orally once daily for 5 days for giardiasis or 7 days for amebiasis) compared to a placebo group receiving similar but not identical placebo capsules. Projected duration of subject participation will be approximately 30 days of face to face visits, including the pre-enrollment screening period of up to 4 days. It is anticipated that it will take approximately 3.5 years to finish the study. Primary objectives are: 1) to compare the proportion of subjects with stools positive by rapid Enzyme Immunoassay (EIA) and positive antigen detection EIA for E. histolytica at enrollment with resolution of diarrhea (less than 3 loose stools/24 hrs) by Day 7 for E. histolytica infections. 2) to compare the proportion of subjects with stools positive by rapid EIA and positive antigen detection EIA for Giardia at enrollment with resolution of diarrhea (less than 3 loose stools/24 hrs) by Day 5 for Giardia infections.
This is a phase IIa, randomized, placebo-controlled, single-blinded superiority treatment study in males and non-pregnant females, 18 to 65 years of age who are in good health. This study is designed to compare placebo to once daily doses of 6mg auranofin for adults with amebiasis or giardiasis. A sample size of 68 subjects enrolled with amebiasis (34 per arm) and 68 with giardiasis (34 per arm); Power based on 60 subjects with amebiasis and 60 with giardiasis completing the study. Eligible subjects will be randomly assigned to a treatment group with auranofin (6 mg orally once daily for 5 days for giardiasis or 7 days for amebiasis) compared to a placebo group receiving similar but not identical placebo capsules. Projected duration of subject participation will be approximately 30 days of face to face visits, including the pre-enrollment screening period of up to 4 days. It is anticipated that it will take approximately 3.5 years to finish the study. Primary objectives are: 1) to compare the proportion of subjects with stools positive by rapid Enzyme Immunoassay (EIA) and positive antigen detection EIA for E. histolytica at enrollment with resolution of diarrhea (less than 3 loose stools/24 hrs) by Day 7 for E. histolytica infections. 2) to compare the proportion of subjects with stools positive by rapid EIA and positive antigen detection EIA for Giardia at enrollment with resolution of diarrhea (less than 3 loose stools/24 hrs) by Day 5 for Giardia infections. Secondary objectives for E. histolytica infections are: 1) to compare the proportion of subjects with stools positive by rapid EIA and positive antigen detection EIA for E. histolytica and trophozoites on smear at enrollment with parasitological response (no detection of trophozoites of E. histolytica on microscopic exam) by Day 7; 2) to compare the proportion of subjects with stools positive rapid EIA and positive antigen detection EIA for E. histolytica and trophozoites on smear at enrollment with parasitological response (no detection of trophozoites on microscopic exam or negative antigen detection) by Days 3 and 5; 3) to compare the rate of decrease of trophozoites/cyst load by Quantitative Polymerase Chain Reaction (qPCR) in stools by Days 3, 5, and 7; 4) to compare the proportion of subjects with negative stool antigen tests by days 3, 5, 7, and 14; 5) to compare the proportion of subjects with sustained cure (no detection of trophozoites by microscopic exam) at 14 and 28 days; 6) to compare the proportion of subjects with relapse (same strain) or re-infection (new strain) with positive stools at 14 and 28 days by genotyping the initial vs. subsequent strain; 7) to compare the time to resolution of diarrhea (less than 3 loose stools/24 hours). Secondary objectives for Giardia infections are: 1) to compare the proportion of subjects with parasitological response (no detection of trophozoites on microscopic exam ) on Day 3, and 5; 2) to compare the rate of decrease of trophozoites/cyst load by qPCR in stools by Days 3 and 5; 3) to compare the proportion of subjects with negative stool antigens by days 3 and 5; 4) to compare the proportion of subjects with sustained cure (no detection of trophozoites by microscopic exam) at 14 and 28 days; 5) to compare the proportion of subjects with relapse (same strain) or re-infection (new strain) with positive stools at 14 and 28 days by genotyping the initial vs. subsequent strain; 6) to compare the time to resolution of diarrhea (less than 3 loose stools/24 hours).
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,448 studies on the registry; 180 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 302 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Amebiasis or giardiasis identified by rapid Enzyme Immunoassay (EIA) and positive antigen detection EIA of stool
Has diarrhea (defined as three or more loose stools) in the past 24 hrs, but is assessed to be clinically stable and in otherwise good health
Women of reproductive potential must have a negative urine pregnancy test within 72 hours of starting study medications.
Female subjects participating in sexual activity that could lead to pregnancy must be using and continue to use highly effective contraception for a total of 4 months after enrollment.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
N=34, 6mg auranofin daily x 7 days
Drug: Auranofin
N=34, 6mg placebo daily x 7 days
Other: Placebo
N=34, 6mg auranofin daily x 5 days
Drug: Auranofin
N=34, 6mg placebo daily x 5 days
Other: Placebo
Auranofin is a gold-containing chemical salt available as 3mg capsules
Placebo
Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)
Diarrhea was assessed by self-report at each study visit. Resolution of diarrhea occurred when participants reported less than 3 loose stools in 24 hours.
Time frame: Day 5
Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)
Participants provided stool samples on Day 5. Stool samples were assessed for parasitological response by detection of cysts or trophozoites via microscopic exam or a negative antigen test.
Time frame: Day 5
Proportion of Participants With Negative Giardia Stool Antigens
Participants provided stool samples on Days 3 and 5. Stool samples were tested for Giardia using antigen detection EIA. Proportions are calculated as the number of participants with negative Giardia stool antigen tests divided by the number of participants with results available.
Time frame: Day 3 through Day 5
Proportion of Symptomatic Participants With Positive Rapid EIA and Positive Antigen Detection EIA for Giardia and Trophozoites on Smear at Enrollment With Parasitological Response
Participants provided stool samples on Days 3 and 5. Stool samples were assessed for parasitological response by detection of trophozoites via microscopic exam. Proportions are calculated as the number of participants with parasitological response divided by the number of participants with results available.
Time frame: Day 3 through Day 5
Proportion of Symptomatic Participants With Sustained Giardia Cure (no Detection of Trophozoites by Microscopic Exam)
Participants provided stool samples on Days 14 and 28. Stool samples were assessed for sustained Giardia cure by detection of trophozoites via microscopic exam. Proportion is calculated as the number of participants with sustained cure divided by the number of participants with results available.
Time frame: Day 14 through Day 28
Giardia Trophozoite/Cyst Load by Quantitative Polymerase Chain Reaction (qPCR) in Stools of Symptomatic Participants
Participants provided stool samples on Days 3 and 5. The Giardia trophozoite/cyst load (parasites/uL) for each group was then assessed by Quantitative Polymerase Chain Reaction (qPCR).
Time frame: Day 3 through Day 5
Time to Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)
Diarrhea was assessed by self-report at each study visit. Resolution of diarrhea occurred when participants reported less than 3 loose stools in 24 hours.
Time frame: Day 1 through Day 28
Proportion of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)
Participants provided stool samples on Day3. Stool samples were assessed for parasitological response by detection of cysts or trophozoites via microscopic exam or a negative antigen test. Proportions are calculated as the number of participants with parasitological response divided by the number of participants with results available.
Time frame: Day 3
Giardia Trophozoite/Cyst Load by Quantitative Polymerase Chain Reaction (qPCR) in Stools
Participants provided stool samples on Days 3 and 5. The Giardia trophozoite/cyst load (parasites/uL) for each group was then assessed by Quantitative Polymerase Chain Reaction (qPCR).
Time frame: Day 3 through Day 5
Proportion of Asymptomatic Participants With Sustained Giardia Cure (no Detection of Trophozoites by Microscopic Exam)
Participants provided stool samples on Days 14 and 28. Stool samples were assessed for sustained Giardia cure by detection of cysts or trophozoites via microscopic exam or negative antigen detection. Proportions are calculated as the number of participants with sustained cure divided by the number of participants with results available.
Time frame: Day 14 through Day 28
Proportion of Participants With Relapse (Same Strain) or Re-infection (New Strain) With Giardia-positive Stools by Genotyping the Initial vs. Subsequent Strain
Participants provided stool samples on Days 14 and 28. Any stool that was still positive for Giardia or trophozoites at Days 14 and 28 had DNA genotyping of the parasite performed on de-identified specimens of extracted DNA. The genotypes from initial and final isolates were compared to determine relapse and/or re-infection. Proportion is calculated as the number of participants with relapse or re-infection divided by the number of participants with results available.
Time frame: Day 14 through Day 28
Proportion of Participants With Relapse (Same Strain) or Re-infection (New Strain) With Giardia-positive Stools by Genotyping the Initial vs. Subsequent Strain
Participants provided stool samples on Days 1, 14 and 28. Participants that were positive for Giardia via antigen detection at Day 1 and had a negative antigen detection test followed by a positive antigen detection test had DNA genotyping of the parasite performed on de-identified specimens of extracted DNA. The genotypes from initial (Day 1) and final isolates (Day 14/28) were compared to determine relapse and/or re-infection. Proportion is calculated as the number of participants with relapse or re-infection divided by the number of participants with results available.
Time frame: Day 1 through Day 28
Participants were males and non-pregnant females between 18 to 65 years of age, inclusive, with amebiasis or giardiasis. Asymptomatic participants were recruited from the Mirpur community of Bangladesh by a randomized census. Symptomatic participants were identified by a health professional at either icddr,b or Rajshahi Medical College hospitals. Asymptomatic participants were enrolled from 06NOV2016 to 23APR2017. Symptomatic participants were enrolled from 16JAN2018 to 28JAN2021.
| Milestone | Asymptomatic E. Histolytica- Auranofin | Asymptomatic E. Histolytica- Placebo | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo | Symptomatic E. Histolytica- Auranofin | Symptomatic E. Histolytica- Placebo | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 1 | 17 | 16 | 0 | 0 | 30 | 29 |
| Completed | 0 | 1 | 17 | 16 | 0 | 0 | 22 | 27 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 |
| Withdrew: Covid-19 pandemic | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Diarrhea was assessed by self-report at each study visit. Resolution of diarrhea occurred when participants reported less than 3 loose stools in 24 hours.
| Participants | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo |
|---|---|---|
| Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours) | 28 | 28 |
Participants provided stool samples on Day 5. Stool samples were assessed for parasitological response by detection of cysts or trophozoites via microscopic exam or a negative antigen test.
| Participants | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo |
|---|---|---|
| Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test) | 6 | 6 |
Participants provided stool samples on Days 3 and 5. Stool samples were tested for Giardia using antigen detection EIA. Proportions are calculated as the number of participants with negative Giardia stool antigen tests divided by the number of participants with results available.
| proportion of participants | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo |
|---|---|---|
| Day 3 | 0.45 (0.28 to 0.62) | 0.38 (0.23 to 0.56) |
| Day 5 | 0.55 (0.38 to 0.72) | 0.34 (0.20 to 0.53) |
Participants provided stool samples on Days 3 and 5. Stool samples were assessed for parasitological response by detection of trophozoites via microscopic exam. Proportions are calculated as the number of participants with parasitological response divided by the number of participants with results available.
| proportion of participants | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo |
|---|---|---|
| Day 3 | 0.97 (0.81 to 1.00) | 0.93 (0.77 to 0.99) |
| Day 5 | 0.97 (0.81 to 1.00) | 1.00 (0.86 to 1.00) |
Participants provided stool samples on Days 14 and 28. Stool samples were assessed for sustained Giardia cure by detection of trophozoites via microscopic exam. Proportion is calculated as the number of participants with sustained cure divided by the number of participants with results available.
| proportion of participants | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo |
|---|---|---|
| Day 14 | 0.96 (0.81 to 1.00) | 0.90 (0.73 to 0.97) |
| Day 28 | 0.96 (0.78 to 1.00) | 0.89 (0.72 to 0.97) |
Participants provided stool samples on Days 3 and 5. The Giardia trophozoite/cyst load (parasites/uL) for each group was then assessed by Quantitative Polymerase Chain Reaction (qPCR).
| log parasite load/uL | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo |
|---|---|---|
| Day 3 | 8.6 (7.1 to 10.1) | 9.2 (8.0 to 10.4) |
| Day 5 | 8.2 (6.8 to 9.6) | 8.1 (7.1 to 9.2) |
Diarrhea was assessed by self-report at each study visit. Resolution of diarrhea occurred when participants reported less than 3 loose stools in 24 hours.
| days | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo |
|---|---|---|
| Time to Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours) | 3 (3.0 to 4.0) | 3 (NA to NA) |
Participants provided stool samples on Day3. Stool samples were assessed for parasitological response by detection of cysts or trophozoites via microscopic exam or a negative antigen test. Proportions are calculated as the number of participants with parasitological response divided by the number of participants with results available.
| proportion with parasitological response | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo |
|---|---|---|
| Proportion of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test) | 0.43 (0.21 to 0.67) | 0.29 (0.11 to 0.55) |
Participants provided stool samples on Days 3 and 5. The Giardia trophozoite/cyst load (parasites/uL) for each group was then assessed by Quantitative Polymerase Chain Reaction (qPCR).
| log parasite load/uL | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo |
|---|---|---|
| Day 3 | 7.5 (5.0 to 10) | 9.0 (6.8 to 11.2) |
| Day 5 | 7.1 (4.9 to 9.2) | 8.5 (6.3 to 10.8) |
Participants provided stool samples on Days 14 and 28. Stool samples were assessed for sustained Giardia cure by detection of cysts or trophozoites via microscopic exam or negative antigen detection. Proportions are calculated as the number of participants with sustained cure divided by the number of participants with results available.
| proportion of participants | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo |
|---|---|---|
| Day 14 | 0.29 (0.11 to 0.55) | 0.21 (0.07 to 0.48) |
| Day 28 | 0.29 (0.11 to 0.55) | 0.14 (0.03 to 0.41) |
Participants provided stool samples on Days 14 and 28. Any stool that was still positive for Giardia or trophozoites at Days 14 and 28 had DNA genotyping of the parasite performed on de-identified specimens of extracted DNA. The genotypes from initial and final isolates were compared to determine relapse and/or re-infection. Proportion is calculated as the number of participants with relapse or re-infection divided by the number of participants with results available.
| proportion of participants | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo |
|---|---|---|
| Day 14 - Relapse | 0.58 (0.32 to 0.81) | 0.75 (0.46 to 0.92) |
| Day 14 - Re-infection | 0.33 (0.14 to 0.61) | 0.25 (0.08 to 0.54) |
| Day 28 - Relapse | 0.63 (0.30 to 0.87) | 0.73 (0.43 to 0.91) |
| Day 28 - Re-infection | 0.25 (0.06 to 0.60) | 0.09 (0.00 to 0.40) |
Participants provided stool samples on Days 1, 14 and 28. Participants that were positive for Giardia via antigen detection at Day 1 and had a negative antigen detection test followed by a positive antigen detection test had DNA genotyping of the parasite performed on de-identified specimens of extracted DNA. The genotypes from initial (Day 1) and final isolates (Day 14/28) were compared to determine relapse and/or re-infection. Proportion is calculated as the number of participants with relapse or re-infection divided by the number of participants with results available.
| proportion of participants | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo |
|---|---|---|
| Day 14 - Relapse | 0.08 (0.00 to 0.38) | 0.07 (0.00 to 0.32) |
| Day 14 - Re-infection | 0.00 (0.00 to 0.28) | 0.07 (0.00 to 0.32) |
| Day 28 - Relapse | 0.11 (0.00 to 0.46) | 0.07 (0.00 to 0.34) |
| Day 28 - Re-infection | 0.00 (0.00 to 0.34) | 0.14 (0.03 to 0.41) |
Collected over Adverse events were collected from the time the participants received study product and continued through study day 29.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Asymptomatic E. Histolytica- Placebo | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Asymptomatic Giardia- Auranofin | 0/17 (0%) | 0/17 (0%) | 9/17 (52.9%) |
| Asymptomatic Giardia- Placebo | 0/16 (0%) | 0/16 (0%) | 7/16 (43.8%) |
| Symptomatic Giardia- Auranofin | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Symptomatic Giardia- Placebo | 0/29 (0%) | 0/29 (0%) | 2/29 (6.9%) |
| Event | Asymptomatic E. Histolytica- Placebo | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/1 | 4/17 | 1/16 | 0/30 | 0/29 |
| AstheniaGeneral disorders | 0/1 | 3/17 | 0/16 | 0/30 | 0/29 |
| RashSkin and subcutaneous tissue disorders | 0/1 | 3/17 | 0/16 | 0/30 | 0/29 |
| Respiratory Tract InfectionInfections and infestations | 0/1 | 1/17 | 2/16 | 0/30 | 0/29 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/1 | 0/17 | 2/16 | 0/30 | 0/29 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 2/17 | 0/16 | 0/30 | 0/29 |
| VertigoEar and labyrinth disorders | 0/1 | 1/17 | 1/16 | 0/30 | 2/29 |
| InfluenzaInfections and infestations | 0/1 | 0/17 | 1/16 | 0/30 | 0/29 |
| Vaginal HaemorrhageReproductive system and breast disorders | 0/1 | 0/17 | 1/16 | 0/30 | 0/29 |
| Abdominal PainGastrointestinal disorders | 0/1 | 1/17 | 0/16 | 0/30 | 0/29 |
No analyses performed on the following groups due to no participants enrolled: Asymptomatic E. histolytica- Auranofin, Symptomatic E. histolytica- Auranofin, Symptomatic E. histolytica- Placebo. Because only one participant was enrolled in Asymptomatic E. histolytica- Placebo, no analyses were performed.
| Age, Categorical(Participants) | Asymptomatic E. Histolytica- Placebo | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 17 | 16 | 30 | 29 | 93 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Asymptomatic E. Histolytica- Placebo | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 36 ± 0 | 38.6 ± 9.3 | 33.5 ± 8.2 | 34.2 ± 9.5 | 33.4 ± 9.4 | 34.6 ± 9.2 |
| Sex: Female, Male(Participants) | Asymptomatic E. Histolytica- Placebo | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 10 | 10 | 0 | 1 | 22 |
| Male | 0 | 7 | 6 | 30 | 28 | 71 |
| Ethnicity (NIH/OMB)(Participants) | Asymptomatic E. Histolytica- Placebo | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 17 | 16 | 30 | 29 | 93 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Asymptomatic E. Histolytica- Placebo | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 17 | 16 | 30 | 29 | 93 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Asymptomatic E. Histolytica- Placebo | Asymptomatic Giardia- Auranofin | Asymptomatic Giardia- Placebo | Symptomatic Giardia- Auranofin | Symptomatic Giardia- Placebo | Total |
|---|---|---|---|---|---|---|
| Bangladesh | 1 | 17 | 16 | 30 | 29 | 93 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Mar 2021, 52 months.
Results were first posted in Jan 2023, 1 year 10 months after primary completion. A results delay was requested in Feb 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Auranofin
Dysentery, Amebic
National Institute of Allergy and Infectious Diseases (NIAID) →